Use eConsult services in Epic to support patients with substance use issues

Jun. 2024Important Notices

Providers can now use the two addiction medicine eConsult services in Epic for support when patients present with substance use issues. The eConsults allow providers to communicate with general internal medicine and ob-gyn physician groups specializing in addiction to get recommendations.

To initiate a consultation in Epic for patients with a condition related to substance use, select from the following options:

  • “Electronic Consult/Referral to Alcohol and Drug Treatment”
  • “Addiction Medicine” or “Perinatal Addiction Medicine” for individuals who identify as female and who may have obstetrical or other reproductive health needs

Patients must give verbal, documented consent for this service and are not to be present during the consultation. The eConsult addiction medicine recommendations are documented in the electronic health record and are billable for requesting and responding providers.*

*Depending on the patient's health care provider, they may be charged cost-sharing depending on the terms of their plan.


Recent Announcements

Important announcement – Telehealth submissions

As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.
Sep. 2025Important Notices

October 2025 UPMC for You and UPMC Community HealthChoices Formulary Update

Effective October 1st, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to non-participation in the Medicaid Drug Rebate Program.
Sep. 2025Pharmacy Updates

Biosimilar Medication Formulary Updates

Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products
Sep. 2025Pharmacy Updates